Last €11.10 EUR
Change Today +0.72 / 6.94%
Volume 123.4K
AB On Other Exchanges
EN Paris
As of 8:15 AM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (AB) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/14 - €16.83
52 Week Low
10/16/14 - €7.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AB SCIENCE SA (AB)

Related News

No related news articles were found.

ab science sa (AB) Related Businessweek News

No Related Businessweek News Found

ab science sa (AB) Details

AB Science S.A., a pharmaceutical company, engages in the research, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines in the United States and Europe. Its lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. It is also pursuing eight on-going phase III studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The company markets its Masitinib under the Masivet brand name for the veterinary market in Europe. Its products are used by hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

112 Employees
Last Reported Date: 08/29/14
Founded in 2001

ab science sa (AB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €387.1K
Compensation as of Fiscal Year 2012.

ab science sa (AB) Key Developments

AB Science Announces Publication of Preclinical Data on the Neuroprotective Effect of Masitinib

AB Science SA announced the publication of preclinical study results with masitinib in ischemic stroke. Masitinib is under development in numerous neurological indications, including Alzheimer's disease, progressive multiple sclerosis and amyotrophic lateral sclerosis (ALS), for which there is evidence that mast cells actively participate in pathogenesis, in particular through modulation of the BBB. These current results in ischemic stroke provide further evidence that masitinib can potentially offer an innovative therapeutic solution to neurodegenerative diseases with high medical need.

AB Science Announces Turnover Results for the Third Quarter and Year to Date Ended September 30, 2014

AB Science announced turnover results for the third quarter and year to date ended September 30, 2014. The turnover of AB Science group stands at EUR 532,000 in the third quarter 2014, against EUR 442,000 in the third quarter 2013, up 20%. The turnover of the group amounted to EUR 1,555,000 as of 30 September 2014, against EUR 1,437,000 the previous year, representing a growth of 8%. This revenue is derived from the commercial exploitation of Masitinib in veterinary medicine in EU and USA mainly.

AB Science S.A. Reports Consolidated Earnings Results for the First Half Ended June 30, 2014

AB Science S.A. reported consolidated earnings results for the first half ended June 30, 2014. For the period, total Revenue was EUR 1,023,000 against EUR 995,000 a year ago. Operating loss was EUR 6,706,000 against EUR 6,033,000 a year ago. Net loss was EUR 7,208,000 against EUR 6,349,000 a year ago. Net income for the period attributable to attributable to equity holders of the parent company was EUR 7,208,000 or EUR 0.22 per basic and diluted share against EUR 6,349,000 or EUR 0.20 per basic and diluted share a year ago. Net cash flow from operating activities was EUR 6,405,000 against EUR 7,270,000 a year ago. Acquisitions of fixed assets were EUR 362,000 against EUR 244,000 a year ago. Acquisitions of financial assets were EUR 6,076,000 against EUR 4,200,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB:FP €11.10 EUR +0.72

AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AB.
View Industry Companies

Industry Analysis


Industry Average

Valuation AB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 162.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 138.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at